• Protease and Phosphatase Inhibitor Cocktail: Applied Workflo

  2026-05-29

  Unlock robust protein preservation with the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O). This reagent from APExBIO empowers researchers to maintain phosphorylation states and protein integrity across diverse sample types, enabling reproducible results in cell signaling and proteomics.

• Bifidobacterium Reduces Neuroinflammation in Chronic HE Rats

  2026-05-28

  This study demonstrates that Bifidobacterium, but not fecal microbiota transplantation, attenuates neuroinflammation in rats with chronic hepatic encephalopathy as assessed by [18F]PBR146 PET imaging. These findings highlight the importance of targeted microbial therapies and advanced neuroimaging for understanding gut–liver–brain axis interactions in hepatic encephalopathy.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Applied

  2026-05-28

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect ubiquitin-proteasome system dynamics and modulate NF-κB signaling in cellular infection and inflammation models. This article delivers actionable protocols, advanced assay strategies, and pragmatic troubleshooting, bridging recent mechanistic insights with robust experimental design.

• AEBSF.HCl in Protease-Driven Cell Death: Mechanisms and Assa

  2026-05-27

  Explore how AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) advances research into protease-driven cell death and amyloid-beta inhibition. This article provides new insights linking molecular mechanism to practical assay design, distinguishing itself from existing guides.

• Protease Inhibitor Cocktail (100X H₂O, EDTA Plus): Real-Worl

  2026-05-27

  This article delivers scenario-driven insights into optimizing protein stability for cell viability and lipid droplet assays using the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) (SKU K4003). Drawing on validated workflows and recent literature, it addresses practical challenges in maintaining protein integrity and selecting reliable reagent solutions for sensitive cell and tissue lysate experiments.

• AmpliFold: Enhancing Lateral Flow Assay Sensitivity via Capt

  2026-05-26

  This study introduces the AmpliFold approach, a triggered capture-and-release strategy that significantly improves the sensitivity of lateral flow assays (LFAs) by enabling high-affinity rebinding of analyte complexes. The methodology leverages cleavable biotin linkers and dual-affinity nanoparticles, offering up to 16-fold signal enhancement and demonstrating robust performance in both buffer and serum matrices.

• [18F]PBR146 PET Reveals Bifidobacterium Reduces Neuroinflamm

  2026-05-26

  This study pioneers the use of [18F]PBR146 PET/CT imaging to noninvasively compare the effects of Bifidobacterium and fecal microbiota transplantation on neuroinflammation in a rat model of chronic hepatic encephalopathy. The work demonstrates that Bifidobacterium, but not FMT, significantly inhibits regional neuroinflammation, offering new insights into gut-brain therapeutic strategies.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-05-25

  Explore how Phosphatase Inhibitor Cocktail 1 enables precise protein phosphorylation preservation, with new insights into signaling pathway analysis and phosphoproteomic workflows. Discover unique mechanistic considerations and advanced protocol guidance.

• Protease Inhibitor Cocktail (100X): Precision in Protein Int

  2026-05-25

  Explore how the Protease Inhibitor Cocktail (100X) enables advanced protein degradation prevention in high-demand molecular workflows. This article unpacks unique scientific insights and practical protocols for maximizing data fidelity.

• Phytol in Nuclear Receptor Pathways: Mechanisms, Material De

  2026-05-24

  Explore the multifaceted mechanisms of Phytol in nuclear hormone receptor activation and its unique intersection with nanomaterial phase behavior. This in-depth analysis reveals how Phytol advances RXR signaling studies and provides new insights for material scientists and assay developers alike.

• Talabostat Mesylate (PT-100): Precision Inhibition in Tumor

  2026-05-23

  Talabostat mesylate (PT-100) empowers researchers to dissect the tumor microenvironment by selectively inhibiting DPP4 and FAP, offering robust modulation of immune and stromal interactions. This guide delivers actionable protocol enhancements, troubleshooting, and insights from high-throughput phenotypic screening, setting a new standard for reproducible, data-rich oncology assays.

• CARD8 Inflammasome Activation Drives Pyroptosis in Human T C

  2026-05-22

  The referenced study demonstrates that inhibition of dipeptidyl peptidases by PT-100 (Talabostat mesylate) uniquely activates the CARD8 inflammasome, leading to pyroptotic cell death in resting human T cells. These findings uncover a previously unrecognized mechanism of T cell regulation, expanding the landscape of inflammasome biology and its potential therapeutic implications in immune modulation.

• Caspase-4 Colorimetric Assay Kit: Precision in Pyroptosis Wo

  2026-05-22

  Unlock reproducible, quantitative detection of caspase-4 activity using the Caspase-4 Colorimetric Assay Kit for advanced pyroptosis, inflammation, and cell fate studies. This guide details protocol enhancements, troubleshooting strategies, and connects recent ER-targeted research advances to practical assay design.

• Leupeptin Hemisulfate Salt: Precision in Protease Activity R

  2026-05-21

  Leupeptin hemisulfate salt delivers nanomolar-level precision for protease activity regulation, enabling advanced workflows in protein degradation, viral replication, and autophagy studies. This guide unpacks workflow enhancements, troubleshooting insights, and the translational edge that Leupeptin, Microbial (Leupeptin hemisulfate) from APExBIO brings to high-impact research.

• Phellodendrine Chloride Attenuates Gouty Arthritis via IL-6/

  2026-05-21

  Qin et al. demonstrate that phellodendrine chloride alleviates gouty arthritis by targeting the IL-6/STAT3 signaling pathway, reducing inflammation and preserving cartilage integrity. Their rigorous in vivo and in vitro approach highlights new therapeutic directions for controlling joint damage in gout.

636 records 7/43 page Previous Next First page 上5页 678910 下5页 Last page